Becky A Briesacher1, Susan E Andrade, Hassan Fouayzi, K Arnold Chan. 1. Division of Geriatric Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Meyers Primary Care Institute, Worcester, MA 01605, USA. Becky.Briesacher@umassmed.edu
Abstract
STUDY OBJECTIVE: To compare drug adherence rates among patients with gout, hypercholesterolemia, hypertension, hypothyroidism, osteoporosis, seizure disorders, and type 2 diabetes mellitus by using a standardized approach. DESIGN: Longitudinal study. DATA SOURCE: Health care claims data from 2001-2004. PATIENTS: A total of 706,032 adults aged 18 years or older with at least one of the seven medical conditions and with incident use of drug therapy for that condition. MEASUREMENTS AND MAIN RESULTS: Drug adherence was measured as the sum of the days' supply of drug therapy over the first year observed. Covariates were age, sex, geographic residence, type of health plan, and a comorbidity score calculated by using the Hierarchical Condition Categories risk adjuster. Bivariate statistics and stratification analyses were used to assess unadjusted means and frequency distributions. Sample sizes ranged from 4984 subjects for seizure disorders to 457,395 for hypertension. During the first year of drug therapy, 72.3% of individuals with hypertension achieved adherence rates of 80% or better compared with 68.4%, 65.4%, 60.8%, 54.6%, 51.2%, or 36.8% for those with hypothyroidism, type 2 diabetes, seizure disorders, hypercholesterolemia, osteoporosis, or gout, respectively. Age younger than 60 years was associated with lower adherence across all diseases except seizure disorders. Comorbidity burden and adherence varied by disease. As comorbidity increased, adherence among subjects with osteoporosis decreased, whereas adherence among those with hypertension, hypercholesterolemia, or gout increased. Add-on drug therapies and previous experience with taking drugs for the condition increased adherence among subjects with hypertension, type 2 diabetes, hypothyroidism, or seizure disorders but not the other conditions. CONCLUSION: This uniform comparison of drug adherence revealed modest variation across six of seven diseases, with the outlier condition being gout.
STUDY OBJECTIVE: To compare drug adherence rates among patients with gout, hypercholesterolemia, hypertension, hypothyroidism, osteoporosis, seizure disorders, and type 2 diabetes mellitus by using a standardized approach. DESIGN: Longitudinal study. DATA SOURCE: Health care claims data from 2001-2004. PATIENTS: A total of 706,032 adults aged 18 years or older with at least one of the seven medical conditions and with incident use of drug therapy for that condition. MEASUREMENTS AND MAIN RESULTS: Drug adherence was measured as the sum of the days' supply of drug therapy over the first year observed. Covariates were age, sex, geographic residence, type of health plan, and a comorbidity score calculated by using the Hierarchical Condition Categories risk adjuster. Bivariate statistics and stratification analyses were used to assess unadjusted means and frequency distributions. Sample sizes ranged from 4984 subjects for seizure disorders to 457,395 for hypertension. During the first year of drug therapy, 72.3% of individuals with hypertension achieved adherence rates of 80% or better compared with 68.4%, 65.4%, 60.8%, 54.6%, 51.2%, or 36.8% for those with hypothyroidism, type 2 diabetes, seizure disorders, hypercholesterolemia, osteoporosis, or gout, respectively. Age younger than 60 years was associated with lower adherence across all diseases except seizure disorders. Comorbidity burden and adherence varied by disease. As comorbidity increased, adherence among subjects with osteoporosis decreased, whereas adherence among those with hypertension, hypercholesterolemia, or gout increased. Add-on drug therapies and previous experience with taking drugs for the condition increased adherence among subjects with hypertension, type 2 diabetes, hypothyroidism, or seizure disorders but not the other conditions. CONCLUSION: This uniform comparison of drug adherence revealed modest variation across six of seven diseases, with the outlier condition being gout.
Authors: Y Zhao; R P Ellis; A S Ash; D Calabrese; J Z Ayanian; J P Slaughter; L Weyuker; B Bowen Journal: Health Serv Res Date: 2001-12 Impact factor: 3.402
Authors: Daniel H Solomon; Jerry Avorn; Jeffrey N Katz; Joel S Finkelstein; Marilyn Arnold; Jennifer M Polinski; M Alan Brookhart Journal: Arch Intern Med Date: 2005-11-14
Authors: P Michael Ho; John S Rumsfeld; Frederick A Masoudi; David L McClure; Mary E Plomondon; John F Steiner; David J Magid Journal: Arch Intern Med Date: 2006-09-25
Authors: M Alan Brookhart; Amanda R Patrick; Colin Dormuth; Jerry Avorn; William Shrank; Suzanne M Cadarette; Daniel H Solomon Journal: Am J Epidemiol Date: 2007-05-15 Impact factor: 4.897
Authors: Somesh Nigam; Naunihal S Virdi; Mehmet Daskiran; Chris M Kozma; Andrew Paris; William M Dickson Journal: J Diabetes Sci Technol Date: 2012-05-01
Authors: Sophie L Stocker; Andrew J McLachlan; Radojka M Savic; Carl M Kirkpatrick; Garry G Graham; Kenneth M Williams; Richard O Day Journal: Br J Clin Pharmacol Date: 2012-09 Impact factor: 4.335
Authors: Michael J Stirratt; Jacqueline Dunbar-Jacob; Heidi M Crane; Jane M Simoni; Susan Czajkowski; Marisa E Hilliard; James E Aikens; Christine M Hunter; Dawn I Velligan; Kristen Huntley; Gbenga Ogedegbe; Cynthia S Rand; Eleanor Schron; Wendy J Nilsen Journal: Transl Behav Med Date: 2015-07-09 Impact factor: 3.046
Authors: Ted R Mikuls; T Craig Cheetham; Gerald D Levy; Nazia Rashid; Artak Kerimian; Kimberly J Low; Brian W Coburn; David T Redden; Kenneth G Saag; P Jeffrey Foster; Lang Chen; Jeffrey R Curtis Journal: Am J Med Date: 2018-11-29 Impact factor: 4.965
Authors: Shira H Fischer; Terry S Field; Shawn J Gagne; Kathleen M Mazor; Peggy Preusse; George Reed; Daniel Peterson; Jerry H Gurwitz; Jennifer Tjia Journal: J Gen Intern Med Date: 2012-11-15 Impact factor: 5.128